Citations

Clear

3030 citation(s) found for "Susan, M".

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
Novak, Anne J. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Mondello, Patrizia , Famà, Angelo , Larson, Melissa C. , Yang, Zhi-Zhang , Villasboas, José C. , Feldman, Andrew L. , Slager, Susan L. , Link, Brian K. , Syrbu, Sergei , Habermann, Thomas M. , Witzig, Thomas E. , Cerhan, James R.

Mayo Clinic

Blood | February 14, 2020 | Volume: 134 | Issue: Supplement_1 | Pages: 121-121

10.1182/blood-2019-126233 Get It

Background: Follicular lymphoma (FL) is the most frequent indolent lymphoma. While immunochemotherapy (IC) treated FL patients who achieve event-free status at 24 months after diagnosis (EFS24) have the subsequent life expectancy of the general population, those who fail to achieve EFS24 have aggressive disease with poor outcomes. Similarly, in FL patients initially observed or treated with rituximab monotherapy, EFS at 12 months (EFS12) is a strong predictor of subsequent outcome. Thus, an unmet patient need is to predict at diagnosis those at greatest risk of early failure in order to identify better treatments. The lymphoma microenvironment may be a key determinant of early failure. Therefore, we aimed to improve risk stratification of newly diagnosed FL patients by using a discovery and validation study design to identify microenvironment determinants of early failure and then integrate them into the Follicular Lymphoma International Prognostic Index (FLIPI). Patients and Methods: We evaluated 496 patients with FL grade 1-3A who were prospectively enrolled into the Molecular Epidemiology Resource (MER) cohort from 2002-2012. In the discovery set of patients (N=166), we stained tissue microarrays for CD4, CD8, FOXP3, CD32b, CD14, CD68, CD70, SIRPa, TIM3, PD-1 and PDL1. Immunohistochemical staining was determined both within and between malignant follicles. Stains were scored to the nearest decile as the percentages of cells positive. Scores for each stain were dichotomized as 0% vs >0% except for CD32b (<20% vs ≥20%), CD70 (<10% vs ≥10%), and SIRPa (<30% vs ≥30%). EFS was defined as time from diagnosis to progression, relapse, retreatment, or death. Early failure was defined as failing to achieve EFS24 for patients treated with IC at diagnosis and failing to achieve EFS12 for patients who were observed or received other treatments. Risk of early failure was estimated using odds ratios (ORs) and 95% confidence intervals (CI) from logistic regression models. Markers at P≤0.15 were brought forward for validation in a separate set of patients from the MER cohort (N=330), with P<0.005 being declared statistically significant after a Bonferroni correction (0.05/10 tests). In the combined dataset, we also used Cox regression to assess associations with continuous EFS and overall survival (OS). Mass cytometry (CyTOF) was then performed on a subset of patients (N=51) to comprehensively characterize the phenotype of intratumoral immune cells associated with outcome. Results: In the discovery set, CD4, CD8, FOXP3, PD-1, and SIRPα were associated with risk of early failure at P≤0.15 and were subsequently evaluated in the validation set. Only CD4 expression inside the follicle validated. Specifically, lack of CD4 expression inside the follicle was associated with higher risk of early failure in the discovery (OR=1.77, P=0.15) and validation (OR=2.59, P=0.001) sets, with a pooled OR=2.29 (95% CI 1.47-3.58; P<0.001). CyTOF analysis characterized the favorable CD4+ T-cell population associated with achieving EFS12/24 as activated effector memory T cells lacking exhaustion markers (Figure 1A). Adjustment of CD4 expression for FLIPI in the combined dataset did not weaken this association (OR=2.38, 95% CI 1.51-3.79), and lack of CD4 expression was prognostic within each FLIPI group 0-1 (OR=2.65; p=0.036), 2 (OR=2.07; P=0.064) and 3-5 (OR=2.51; P=0.015). We next established a bio-clinical risk model (termed BioFLIPI) that combined CD4 intrafollicular expression and FLIPI into a 1-4 scale, where any expression of intrafollicular CD4 moved a patient up one FLIPI risk group, adding a fourth (high) risk group for FLIPI 3-5 and any CD4 inside expression. The BioFLIPI score was strongly associated with risk of early failure: compared to a BioFLIPI score of 1 (24% of patients), patients with a score of 2 (35% of patients; OR=2.17, 95% CI 1.08-4.69), 3 (31% of patients; OR=3.53, 95% CI 1.78-7.54), and 4 (10% of patients; OR=8.92, 95% CI 4.00-21.1) had increasing risk of early failure. The c-statistic for BioFLIPI was 0.665, which was higher than that for FLIPI alone (0.636). BioFLIPI was also strongly predictive of continuous EFS [Figure 1B], OS [Figure 1C], and for EFS and EFS24 when restricted to IC-treated patients [Figure 1D]. Conclusion: Integration of CD4 expression inside the follicle at diagnosis with FLIPI improves identification of FL patients at risk for early failure. Disclosures Novak: Celgene Coorperation: Research Funding. Nowakowski:Curis: Research Funding; Bayer: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; F. Hoffmann-La Roche Ltd: Research Funding; Selvita: Membership on an entity's Board of Directors or advisory committees; NanoString: Research Funding; Genentech, Inc.: Research Funding; MorphoSys: Consultancy, Research Funding. Cerhan:NanoString: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding. Ansell:LAM Therapeutics: Research Funding; Mayo Clinic Rochester: Employment; Affimed: Research Funding; Affimed: Research Funding; Trillium: Research Funding; Bristol-Myers Squibb: Research Funding; Mayo Clinic Rochester: Employment; Affimed: Research Funding; Trillium: Research Funding; Seattle Genetics: Research Funding; Regeneron: Research Funding; Bristol-Myers Squibb: Research Funding; Trillium: Research Funding; Trillium: Research Funding; LAM Therapeutics: Research Funding; Regeneron: Research Funding; LAM Therapeutics: Research Funding; LAM Therapeutics: Research Funding; Seattle Genetics: Research Funding; LAM Therapeutics: Research Funding; Bristol-Myers Squibb: Research Funding; LAM Therapeutics: Research Funding; Regeneron: Research Funding; Bristol-Myers Squibb: Research Funding; LAM Therapeutics: Research Funding; Seattle Genetics: Research Funding; Seattle Genetics: Research Funding; Mayo Clinic Rochester: Employment; Affimed: Research Funding; Bristol-Myers Squibb: Research Funding; Bristol-Myers Squibb: Research Funding; Seattle Genetics: Research Funding; Seattle Genetics: Research Funding; LAM Therapeutics: Research Funding; Trillium: Research Funding; LAM Therapeutics: Research Funding; Affimed: Research Funding; Regeneron: Research Funding; Trillium: Research Funding; Mayo Clinic Rochester: Employment; Regeneron: Research Funding; Seattle Genetics: Research Funding; Regeneron: Research Funding; Bristol-Myers Squibb: Research Funding; Trillium: Research Funding; Regeneron: Research Funding; Mayo Clinic Rochester: Employment; Affimed: Research Funding; Mayo Clinic Rochester: Employment; Seattle Genetics: Research Funding; Affimed: Research Funding; Bristol-Myers Squibb: Research Funding; Bristol-Myers Squibb: Research Funding; Affimed: Research Funding; Trillium: Research Funding; Regeneron: Research Funding; Affimed: Research Funding; Trillium: Research Funding; Mayo Clinic Rochester: Employment; Regeneron: Research Funding; Seattle Genetics: Research Funding; Mayo Clinic Rochester: Employment; Mayo Clinic Rochester: Employment.
Phase I study of AR-42 and decitabine in acute myeloid leukemia
Liva, Sophia G. , Coss, Christopher C. , Wang, Jiang , Blum, William , Klisovic, Rebecca B. , Bhatnagar, Bhavana , Walsh, Katherine, Geyer, Susan M. , Zhao, Qiuhong , Garzon, Ramiro , Marcucci, Guido , Phelps, Mitch A. , Walker, Alison R. , Phelps, Mitch

Mayo Clinic

Leukemia & Lymphoma | February 8, 2020 | Volume: 61 | Issue: 6 | Pages: 1484-1492

10.1080/10428194.2020.1719095 | PMID 32037935 Get It

Artificial intelligence in sleep medicine: an American Academy of Sleep Medicine position statement
Goldstein, Cathy , Berry, Richard B. , Kent, David T. , Kristo, David A., Seixas, Azizi , Redline, Susan , Westover, M. Brandon , Abbasi-Feinberg, Fariha, Aurora, R. Nisha , Carden, Kelly A., Kirsch, Douglas B. , Malhotra, Raman K. , Olson, Eric J. , Ramar, Kannan , Rosen, Carol L. , Rowley, James A. , Shelgikar, Anita V., Kent, David , Westover, M Brandon , Martin, Jennifer L.

Mayo Clinic

Journal of Clinical Sleep Medicine | February 5, 2020 | Volume: 16 | Issue: 4 | Pages: 605-607

10.5664/jcsm.8288 | PMID 32022674 Get It

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study.
Schneider, Bryan J. , Abushahin, Laith , Birdas, Thomas J. , Kesler, Kenneth A., Burney, Heather , Perkins, Susan M. , Jalal, Shadia I. , Mamdani, Hirva Mansurali , Kasi, Pashtoon Murtaza

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: 404-404

10.1200/jco.2020.38.4_suppl.404 Get It

404 Background: Concurrent chemoradiation(CRT) followed by esophagectomy is a standard of care for locally advanced esophageal(LA-EAC) and GEJ adenocarcinoma. Approximately 50% of patients(pts) experience disease relapse within the 1st yr after treatment(tx) completion. No adjuvant tx has been shown to improve survival in these pts. Immune checkpoint inhibitors have activity in metastatic PD-L1 positive EAC. Preclinical studies have shown radiation +/- chemotherapy upregulate PD-1/PD-L1 pathway. Methods: We conducted a phase II trial evaluating safety and efficacy of durvalumab(durva) in pts with LA-EAC and GEJ adenocarcinoma who have residual disease in surgical specimen after neoadjuvant CRT and R0 resection. Pts received durva 1500mg IV every 4 weeks for up to 1yr. Results: 24 pts were enrolled from 4/2016-1/2018(median age: 60yrs (range, 43-70). 18 received carbo/paclitaxel and 6 received cis/5-FU concurrently with radiation. Staging at diagnosis: T2N0(n = 3, 12.5%), T2N2(n = 3, 12.5%),T3N0(n = 6, 25%), T3N1(n = 6, 25%), T3N2(n = 4, 17%), T3N3(n = 1, 4%), T3Nx(n = 1, 4%).19 pts(79%) had positive lymph nodes(LNs) at the time of surgery following CRT. 12 pts completed 1yr of tx, 12 came off tx because of relapse(6), AEs(5), and consent withdrawal(1). Most common AEs were fatigue(n = 8, 33.3%) and nausea(n = 6, 25%). 3pts (12.5%) developed grade 3 irAEs: pneumonitis(1), hepatitis(1), colitis(1). At median follow up of 21.9mo(range, 1.7-23.9mo), 11 pts have relapsed: 9 distant and 2 locoregional. Two of 3 pts with grade 3 irAEs are alive and disease free at 17 and 23 mo respectively. 1-yr RFS and OS were 79.2% and 95.5%, respectively. RFS at 26 mo was 20.6%. Overall mOS and mOS after relapse were 28.1mo(range, 22.9-28.1) and 11.1 mo(range, 0.1-11.3mo) respectively. The study was expanded to enroll 14 additional pts who are currently undergoing tx. Conclusions: Adjuvant durvalumab following trimodality therapy for LA-EAC and GEJ adenocarcinoma is safe with improvement in 1-yr RFS to 79.2% compared to historical rate of 50%. RFS was 20.6% at 26 months. Evaluation of predictive biomarkers of RFS with durva is underway. Clinical trial information: NCT02639065.
Exploring the Networking of Academic Health Science Leaders: How and Why Do They Do It?
Lieff, Susan, Poost-Foroosh, Laya, Castellani, Brian , Hafferty, Frederic W. , Baker, Lindsay R. , Ng, Stella

Mayo Clinic

Academic Medicine | January 29, 2020 | Volume: 95 | Issue: 10 | Pages: 1570-1577

10.1097/acm.0000000000003177 | PMID 31996558 Get It

Purpose Networking is essential to leadership effectiveness in the business context. Yet little is known about leadership networking within the academic health science context. If we are going to train academic leaders, we must first understand the relational, network-based activities of their work. The purpose of this study was to explore how academic health science leaders engage in networking activities in the academic health science context. Method A constructivist grounded theory approach guided our study. The authors interviewed 24 academic health science leaders who were enrolled in the New and Evolving Academic Leadership program at the University of Toronto and used social network mapping as an elicitation method. Interviews, which were conducted between September 2014 and June 2015, explored participants’ networks and networking activities. Constant comparative analysis was used to analyze the interviews, with attention paid to identifying key networking activities. Results Academic health science leaders were found to engage in 4 types of networking activities: role bound, project based, goal/vision informed, and opportunity driven. These 4 types were influenced by participants’ conception of their role and their perceived leadership work context, which in turn influenced their sense of agency. Conclusions The networking activities identified in this study of academic health science leaders resonate with effective networking activities found in other fields. The findings highlight that these activities can be facilitated by focusing on leaders’ perceptions about role and work context. Leadership development should thus attend to these perceptions to encourage effective networking skills.
Improved Stable Isotope Dilution-Gas Chromatography-Mass Spectrometry Method for Serum or Plasma Free 3-Hydroxy-Fatty Acids and Its Utility for the Study of Disorders of Mitochondrial Fatty Acid β-Oxidation
Jones, Patricia M, Quinn, Rebecca, Fennessey, Paul V., Tjoa, Susan, Goodman, Stephen I., Fiore, Stephany, Rinaldo, Piero, Boriack, Richard L., Bennett, Michael J, Jones, Patricia M, Burlina, Alberto , Bennett, Michael J

Mayo Clinic

Clinical Chemistry | January 23, 2020 | Volume: 46 | Issue: 2 | Pages: 149-155

10.1093/clinchem/46.2.149 Get It

Abstract Background: Disorders of fatty acid oxidation (FAO) are difficult to diagnose, primarily because in many of the FAO disorders measurable biochemical intermediates accumulate in body fluids only during acute illness. Increased concentrations of 3-hydroxy-fatty acids (3-OH-FAs) in the blood are indicative of FAO disorders of the long- and short-chain 3-hydroxy-acyl-CoA dehydrogenases, LCHAD and SCHAD. We describe a serum/plasma assay for the measurement of 3-OH-FAs with carbon chain lengths from C6 to C16. Methods: We used stable isotope dilution gas chromatography-mass spectrometry (GC-MS) with electron impact ionization and selected ion monitoring. Natural and isotope-labeled compounds were synthesized for the assay. Results: The assay was linear from 0.2 to 50 μmol/L for all six 3-OH-FAs. CVs were 5–15% at concentrations near the upper limits seen in healthy subjects. In 43 subjects, the medians (and ranges) in μmol/L were as follows: 3-OH-C6, 0.8 (0.3–2.2); 3-OH-C8, 0.4 (0.2–1.0); 3-OH-C10, 0.3 (0.2–0.6); 3-OH-C12, 0.3 (0.2–0.6); 3-OH-C14, 0.2 (0.0–0.4); and 3-OH-C16, 0.2 (0.0–0.5). 3-OH-FAs were increased in infants receiving formula containing medium chain triglycerides. Two patients diagnosed with LCHAD deficiency showed marked increases in 3-OH-C14 and 3-OH-C16 concentrations. Two patients diagnosed with SCHAD deficiency showed increased shorter chain 3-OH-FAs but no increases in 3-OH-C14 to 3-OH-C16. Conclusion: Measuring blood concentrations of the 3-OH-FAs with this assay may be a valuable tool for helping to rapidly identify deficiencies in LCHAD and SCHAD and may also provide useful information about the status of the FAO pathway.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
Lee, Eudocia Q. , Weller, Michael , Sul, Joohee, Bagley, Stephen , Sahebjam, Solmaz , Bent, Martin J. van den , Ahluwalia, Manmeet S. , Campian, Jian , Holdhoff, Matthias , Lesser, Glenn J. , Lieberman, Frank S. , Peñas-Prado, Marta , Schreck, Karisa C. , Vogelbaum, Michael A. , Walbert, Tobias , Chang, Susan M. , Reardon, David A. , Wen, Patrick Y. , Weller, Michael , van den Bent, Martin J , Ahluwalia, Manmeet S , Galanis, Evanthia , Gilbert, Mark R. , Mehta, Minesh P. , Strowd, Roy E. , Chang, Susan Marina , Nabors, Burt , Grossman, Stuart A. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | January 23, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noaa015 | PMID 31974566 Get It

AbstractBuilding on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.
Diversity and inclusion in pain medicine
Hagedorn, Jonathan M. , Moeschler, Susan M. , Goree, Johnathan , Weisbein, Jackie, Moeschler, Susan, Hagedorn, Jonathan M , Weisbein, Jacqueline S. , Deer, Timothy R.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 22, 2020 | Volume: 45 | Issue: 10 | Pages: 839-839

10.1136/rapm-2020-101284 | PMID 31969441 Get It